SCHEMBL13620366

SCHEMBL13620366

CC(C)Oc1ccc(CC(NC(=O)c2ccc(OCC3CC3)cc2)C(=O)NCCO)cc1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CTSS P25774 4/20 0.54
CTSL P07711 4/20 0.54
ACACB O00763 4/20 0.46
CTSK P43235 1/20 0.45
PLG P00747 3/20 0.44
PRSS1 P07477 2/20 0.44
PRSS2 P07478 2/20 0.44
PRSS3 P35030 2/20 0.44
L3MBTL1 Q9Y468 1/20 0.44
KMT2A Q03164 1/20 0.44
TACR2 P21452 1/20 0.43
NR1H4 Q96RI1 1/20 0.43
KLKB1 P03952 1/20 0.43
NPC1 O15118 1/20 0.43
HPGD P15428 1/20 0.43
RAB9A P51151 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
PDE4A P27815 1/20 0.42
PDE4B Q07343 1/20 0.42
PDE4C Q08493 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4376004 0.91 CTSS (0.50) CTSSCTSLACACBCTSKPLG
SCHEMBL4370281 0.91 CTSS (0.50) CTSSCTSLACACBCTSKPLG
SCHEMBL4375994 0.90 KLKB1 (0.52) CTSSCTSLACACBPLGPRSS1
SCHEMBL4376250 0.90 CTSL (0.51) CTSSCTSLACACBPLGPRSS1
SCHEMBL4367199 0.88 CTSL (0.48) CTSSCTSLACACBCTSKPLG
SCHEMBL4361645 0.88 CTSL (0.48) CTSSCTSLACACBPLGPRSS1
SCHEMBL4372754 0.87 PLG (0.52) CTSSCTSLACACBPLGPRSS1
SCHEMBL4369015 0.87 PLG (0.52) CTSSCTSLACACBPLGPRSS1
SCHEMBL4369891 0.86 CTSS (0.56) CTSSCTSLACACBCTSKPLG
SCHEMBL4368444 0.86 KLKB1 (0.53) CTSSCTSLACACBCTSKPLG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8344029-B2 Substituted propanamide derivative and pharmaceutical composition containing the same DAIICHI SANKYO COMPANY, LIMITED (JP) 2013-01-01 US disclosed
US-8344029-B2 Substituted propanamide derivative and pharmaceutical composition containing the same DAIICHI SANKYO COMPANY, LIMITED (JP) 2013-01-01 US disclosed
US-20090292024-A1 SUBSTITUTED PROPANAMIDE DERIVATIVE AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME DAIICHI SANKYO COMPANY, LIMITED (JP) 2009-11-26 US disclosed
US-20090292024-A1 SUBSTITUTED PROPANAMIDE DERIVATIVE AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME DAIICHI SANKYO COMPANY, LIMITED (JP) 2009-11-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090292024-A1 SUBSTITUTED PROPANAMIDE DERIVATIVE AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME PTMS, C1S, ACP3 CTSS 416/4885CTSL 530/4885ACACB 735/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.